Loading...

Cybin Inc.

CYBN.NENEO
Healthcare
Biotechnology
CA$10.07
CA$0.22(2.23%)

Cybin Inc. (CYBN.NE) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Cybin Inc. (CYBN.NE), covering cash flow, earnings, and balance sheets.

Revenue Growth
0.00%
Operating Income Growth
-43.49%
43.49%
Net Income Growth
-64.41%
64.41%
Operating Cash Flow Growth
-45.28%
45.28%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-38.95%
38.95%
ROIC
-56.22%
56.22%

Cybin Inc. (CYBN.NE) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Cybin Inc. CYBN.NE financial performance.

MetricQ3 2025Q2 2025Q1 2025Q4 2024
Revenue$0.00$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$138000.00$142000.00
Gross Profit$0.00$0.00-$138000.00-$142000.00
Gross Profit Ratio$0.00$0.00$0.00$0.00
R&D Expenses$19.72M$9.44M$8.04M$11.84M
SG&A Expenses$11.58M$48.82M$12.28M$13.36M
Operating Expenses$31.30M$58.25M$20.32M$25.05M
Total Costs & Expenses$31.30M$58.25M$20.32M$25.20M
Interest Income$1.63M$3.08M$2.14M$342000.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$132000.00$143000.00$138000.00$142000.00
EBITDA-$31.17M-$58.11M-$20.18M-$25.05M
EBITDA Ratio$0.00$0.00$0.00$0.00
Operating Income-$31.30M-$58.25M-$20.32M-$25.20M
Operating Income Ratio$0.00$0.00$0.00$0.00
Other Income/Expenses (Net)$20.76M$1.06M$5.49M$3.85M
Income Before Tax-$10.54M-$57.19M-$14.82M-$21.35M
Income Before Tax Ratio$0.00$0.00$0.00$0.00
Income Tax Expense$0.00$0.00$0.00$0.00
Net Income-$10.54M-$57.19M-$14.82M-$21.35M
Net Income Ratio$0.00$0.00$0.00$0.00
EPS-$0.53-$2.86-$0.74-$0.03
Diluted EPS-$0.53-$2.86-$0.74-$0.03
Weighted Avg Shares Outstanding$20.001M$20.001M$19.59M$20.001M
Weighted Avg Shares Outstanding (Diluted)$20.001M$20.001M$19.59M$20.001M

Financial performance has remained strong, with revenue growing from $0.00 in Q4 2024 to $0.00 in Q3 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$31.30M in Q3 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$31.17M. Net income rose to -$10.54M, keeping EPS at -$0.53. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;